Skip to main content
NCBI home page
Clinical Molecular Pathology logoLink to Clinical Molecular Pathology
. 1995 Apr;48(2):M83–M87. doi: 10.1136/mp.48.2.m83

A comparative study of cell proliferation markers in breast carcinomas

A S-Y Leong 1, S Vinyuvat 1, C Suthipintawong 1, J Milios 1
PMCID: PMC407930  PMID: 16695987

Abstract

Aims—To investigate the tumour cell proliferative index obtained by immunostaining of paraffin wax sections of 30 cases of breast carcinoma with monoclonal antibodies MIB1, KiS1 and KiS5, and polyclonal Ki67 antisera to the Ki67 antigen and 19A2 and PC10 antibodies to proliferating cell nuclear antigen and the possible correlation between these indices and that of monoclonal Ki67 antibody in frozen sections of the same tumours.

Methods—All tumour samples had been uniformly fixed and processed and sections were subjected to microwave antigen retrieval before immunostaining in all instances except for monoclonal Ki67 antibody which was used in cryostat sections. Tumour cell proliferative indices were evaluated by two independent examiners, each counting 500 tumour cells with the aid of a cross-hatched grid.

Results—Proliferative indices obtained with MIB1, polyclonal Ki67, KiS1, and KiS5 correlated with those obtained with monoclonal Ki67 in frozen sections. Proliferative indices obtained with monoclonal 19A2 and PC10 showed no correlation with those of monoclonal Ki67 antibody. The staining obtained with MIB1 was the most intense and the easiest to read.

Conclusions—Monoclonal antibodies MIB1, KiS1 and KiS5 and polyclonal Ki67 antiserum appear to be suitable substitutes for monoclonal antibody Ki67 in the assessment of tumour cell proliferative index. As these reagents are all immunoreactive in paraffin wax sections, they overcome the requirement for frozen tissue for immunostaining with monoclonal Ki67.

Keywords: Proliferation markers

Keywords: Ki67

Keywords: breast cancer

Full text

PDF
M83

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baisch H., Gerdes J. Simultaneous staining of exponentially growing versus plateau phase cells with the proliferation-associated antibody Ki-67 and propidium iodide: analysis by flow cytometry. Cell Tissue Kinet. 1987 Jul;20(4):387–391. doi: 10.1111/j.1365-2184.1987.tb01323.x. [DOI] [PubMed] [Google Scholar]
  2. Barbareschi M., Girlando S., Mauri F. M., Forti S., Eccher C., Mauri F. A., Togni R., Dalla Palma P., Doglioni C. Quantitative growth fraction evaluation with MIB1 and Ki67 antibodies in breast carcinomas. Am J Clin Pathol. 1994 Aug;102(2):171–175. doi: 10.1093/ajcp/102.2.171. [DOI] [PubMed] [Google Scholar]
  3. Barnard N. J., Hall P. A., Lemoine N. R., Kadar N. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol. 1987 Aug;152(4):287–295. doi: 10.1002/path.1711520407. [DOI] [PubMed] [Google Scholar]
  4. Bouzubar N., Walker K. J., Griffiths K., Ellis I. O., Elston C. W., Robertson J. F., Blamey R. W., Nicholson R. I. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer. 1989 Jun;59(6):943–947. doi: 10.1038/bjc.1989.200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bravo R., Frank R., Blundell P. A., Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature. 1987 Apr 2;326(6112):515–517. doi: 10.1038/326515a0. [DOI] [PubMed] [Google Scholar]
  6. Brown D. C., Gatter K. C. Monoclonal antibody Ki-67: its use in histopathology. Histopathology. 1990 Dec;17(6):489–503. doi: 10.1111/j.1365-2559.1990.tb00788.x. [DOI] [PubMed] [Google Scholar]
  7. Carey F. A., Fabbroni G., Lamb D. Expression of proliferating cell nuclear antigen in lung cancer: a systematic study and correlation with DNA ploidy. Histopathology. 1992 Jun;20(6):499–503. doi: 10.1111/j.1365-2559.1992.tb01034.x. [DOI] [PubMed] [Google Scholar]
  8. Cattoretti G., Becker M. H., Key G., Duchrow M., Schlüter C., Galle J., Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992 Dec;168(4):357–363. doi: 10.1002/path.1711680404. [DOI] [PubMed] [Google Scholar]
  9. Celis J. E., Celis A. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci U S A. 1985 May;82(10):3262–3266. doi: 10.1073/pnas.82.10.3262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Charpin C., Andrac L., Vacheret H., Habib M. C., Devictor B., Lavaut M. N., Toga M. Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast carcinoma tissue sections. Cancer Res. 1988 Aug 1;48(15):4368–4374. [PubMed] [Google Scholar]
  11. Coon J. S., Landay A. L., Weinstein R. S. Advances in flow cytometry for diagnostic pathology. Lab Invest. 1987 Nov;57(5):453–479. [PubMed] [Google Scholar]
  12. Cuevas E., Jones D. B., Wright D. H. Immunohistochemical detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol. 1993 Apr;169(4):477–478. doi: 10.1002/path.1711690415. [DOI] [PubMed] [Google Scholar]
  13. Dean P. N., Dolbeare F., Gratzner H., Rice G. C., Gray J. W. Cell-cycle analysis using a monoclonal antibody to BrdUrd. Cell Tissue Kinet. 1984 Jul;17(4):427–436. doi: 10.1111/j.1365-2184.1984.tb00601.x. [DOI] [PubMed] [Google Scholar]
  14. Düe W., Dieckmann K. P., Loy V. Immunohistological determination of proliferative activity in seminomas. J Clin Pathol. 1988 Mar;41(3):304–307. doi: 10.1136/jcp.41.3.304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fonatsch C., Duchrow M., Rieder H., Schlüter C., Gerdes J. Assignment of the human Ki-67 gene (MK167) to 10q25-qter. Genomics. 1991 Oct;11(2):476–477. doi: 10.1016/0888-7543(91)90163-9. [DOI] [PubMed] [Google Scholar]
  16. Garcia R. L., Coltrera M. D., Gown A. M. Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. Am J Pathol. 1989 Apr;134(4):733–739. [PMC free article] [PubMed] [Google Scholar]
  17. Gatter K. C., Dunnill M. S., Gerdes J., Stein H., Mason D. Y. New approach to assessing lung tumours in man. J Clin Pathol. 1986 Jun;39(6):590–593. doi: 10.1136/jcp.39.6.590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Gerdes J., Becker M. H., Key G., Cattoretti G. Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol. 1992 Sep;168(1):85–86. doi: 10.1002/path.1711680114. [DOI] [PubMed] [Google Scholar]
  19. Gerdes J., Lemke H., Baisch H., Wacker H. H., Schwab U., Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984 Oct;133(4):1710–1715. [PubMed] [Google Scholar]
  20. Gerdes J., Li L., Schlueter C., Duchrow M., Wohlenberg C., Gerlach C., Stahmer I., Kloth S., Brandt E., Flad H. D. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 1991 Apr;138(4):867–873. [PMC free article] [PubMed] [Google Scholar]
  21. Gerdes J., Schwab U., Lemke H., Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983 Jan 15;31(1):13–20. doi: 10.1002/ijc.2910310104. [DOI] [PubMed] [Google Scholar]
  22. Gerdes J., Stein H., Pileri S., Rivano M. T., Gobbi M., Ralfkiaer E., Nielsen K. M., Pallesen G., Bartels H., Palestro G. Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas. Lancet. 1987 Aug 22;2(8556):448–449. doi: 10.1016/s0140-6736(87)90977-9. [DOI] [PubMed] [Google Scholar]
  23. Grigioni W. F., D'Errico A., Bacci F., Gaudio M., Mazziotti A., Gozzetti G., Mancini A. M. Primary liver neoplasms: evaluation of proliferative index using MoAb Ki67. J Pathol. 1989 May;158(1):23–29. doi: 10.1002/path.1711580107. [DOI] [PubMed] [Google Scholar]
  24. Grogan T. M., Lippman S. M., Spier C. M., Slymen D. J., Rybski J. A., Rangel C. S., Richter L. C., Miller T. P. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood. 1988 Apr;71(4):1157–1160. [PubMed] [Google Scholar]
  25. Hall P. A., Levison D. A. Review: assessment of cell proliferation in histological material. J Clin Pathol. 1990 Mar;43(3):184–192. doi: 10.1136/jcp.43.3.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Hall P. A., Levison D. A., Woods A. L., Yu C. C., Kellock D. B., Watkins J. A., Barnes D. M., Gillett C. E., Camplejohn R., Dover R. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol. 1990 Dec;162(4):285–294. doi: 10.1002/path.1711620403. [DOI] [PubMed] [Google Scholar]
  27. Hall P. A., Richards M. A., Gregory W. M., d'Ardenne A. J., Lister T. A., Stansfeld A. G. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol. 1988 Mar;154(3):223–235. doi: 10.1002/path.1711540305. [DOI] [PubMed] [Google Scholar]
  28. Kamel O. W., Franklin W. A., Ringus J. C., Meyer J. S. Thymidine labeling index and Ki-67 growth fraction in lesions of the breast. Am J Pathol. 1989 Jan;134(1):107–113. [PMC free article] [PubMed] [Google Scholar]
  29. Kaudewitz P., Braun-Falco O., Ernst M., Landthaler M., Stolz W., Gerdes J. Tumor cell growth fractions in human malignant melanomas and the correlation to histopathologic tumor grading. Am J Pathol. 1989 May;134(5):1063–1068. [PMC free article] [PubMed] [Google Scholar]
  30. Key G., Becker M. H., Baron B., Duchrow M., Schlüter C., Flad H. D., Gerdes J. New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest. 1993 Jun;68(6):629–636. [PubMed] [Google Scholar]
  31. Key G., Petersen J. L., Becker M. H., Duchrow M., Schlüter C., Askaa J., Gerdes J. New antiserum against Ki-67 antigen suitable for double immunostaining of paraffin wax sections. J Clin Pathol. 1993 Dec;46(12):1080–1084. doi: 10.1136/jcp.46.12.1080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Kreipe H., Alm P., Olsson H., Hauberg M., Fischer L., Parwaresch R. Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1. Am J Pathol. 1993 Feb;142(2):651–657. [PMC free article] [PubMed] [Google Scholar]
  33. Kreipe H., Wacker H. H., Heidebrecht H. J., Haas K., Hauberg M., Tiemann M., Parwaresch R. Determination of the growth fraction in non-Hodgkin's lymphomas by monoclonal antibody Ki-S5 directed against a formalin-resistant epitope of the Ki-67 antigen. Am J Pathol. 1993 Jun;142(6):1689–1694. [PMC free article] [PubMed] [Google Scholar]
  34. Kurki P., Ogata K., Tan E. M. Monoclonal antibodies to proliferating cell nuclear antigen (PCNA)/cyclin as probes for proliferating cells by immunofluorescence microscopy and flow cytometry. J Immunol Methods. 1988 Apr 22;109(1):49–59. doi: 10.1016/0022-1759(88)90441-3. [DOI] [PubMed] [Google Scholar]
  35. Landolt A. M., Shibata T., Kleihues P. Growth rate of human pituitary adenomas. J Neurosurg. 1987 Dec;67(6):803–806. doi: 10.3171/jns.1987.67.6.0803. [DOI] [PubMed] [Google Scholar]
  36. Lellé R. J., Heidenreich W., Stauch G., Gerdes J. The correlation of growth fractions with histologic grading and lymph node status in human mammary carcinoma. Cancer. 1987 Jan 1;59(1):83–88. doi: 10.1002/1097-0142(19870101)59:1<83::aid-cncr2820590119>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  37. Leonardi E., Girlando S., Serio G., Mauri F. A., Perrone G., Scampini S., Dalla Palma P., Barbareschi M. PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol. 1992 May;45(5):416–419. doi: 10.1136/jcp.45.5.416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Magaud J. P., Sargent I., Clarke P. J., Ffrench M., Rimokh R., Mason D. Y. Double immunocytochemical labeling of cell and tissue samples with monoclonal anti-bromodeoxyuridine. J Histochem Cytochem. 1989 Oct;37(10):1517–1527. doi: 10.1177/37.10.2476478. [DOI] [PubMed] [Google Scholar]
  39. Malaise E. P., Chavaudra N., Tubiana M. The relationship between growth rate, labelling index and histological type of human solid tumours. Eur J Cancer. 1973 Apr;9(4):305–312. doi: 10.1016/0014-2964(73)90099-6. [DOI] [PubMed] [Google Scholar]
  40. Mathews M. B., Bernstein R. M., Franza B. R., Jr, Garrels J. I. Identity of the proliferating cell nuclear antigen and cyclin. Nature. 1984 May 24;309(5966):374–376. doi: 10.1038/309374a0. [DOI] [PubMed] [Google Scholar]
  41. McCormick D., Hall P. A. The complexities of proliferating cell nuclear antigen. Histopathology. 1992 Dec;21(6):591–594. doi: 10.1111/j.1365-2559.1992.tb00454.x. [DOI] [PubMed] [Google Scholar]
  42. McGurrin J. F., Doria M. I., Jr, Dawson P. J., Karrison T., Stein H. O., Franklin W. A. Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast. Cancer. 1987 May 15;59(10):1744–1750. doi: 10.1002/1097-0142(19870515)59:10<1744::aid-cncr2820591012>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  43. Meyer J. S., Friedman E., McCrate M. M., Bauer W. C. Prediction of early course of breast carcinoma by thymidine labeling. Cancer. 1983 May 15;51(10):1879–1886. doi: 10.1002/1097-0142(19830515)51:10<1879::aid-cncr2820511021>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  44. Meyer J. S. Growth and cell kinetic measurements in human tumors. Pathol Annu. 1981;16(Pt 2):53–81. [PubMed] [Google Scholar]
  45. Milios J., Leong A. S. The application of the avidin-biotin technique to previously stained histological sections. Stain Technol. 1987 Nov;62(6):411–416. doi: 10.3109/10520298709108031. [DOI] [PubMed] [Google Scholar]
  46. Miyachi K., Fritzler M. J., Tan E. M. Autoantibody to a nuclear antigen in proliferating cells. J Immunol. 1978 Dec;121(6):2228–2234. [PubMed] [Google Scholar]
  47. Quinn C. M., Wright N. A. The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J Pathol. 1990 Feb;160(2):93–102. doi: 10.1002/path.1711600202. [DOI] [PubMed] [Google Scholar]
  48. Quinn C. M., Wright N. A. The usefulness of clinical measurements of cell proliferation in gynecological cancer. Int J Gynecol Pathol. 1992;11(2):131–143. doi: 10.1097/00004347-199204000-00007. [DOI] [PubMed] [Google Scholar]
  49. Quirke P., Dyson J. E. Flow cytometry: methodology and applications in pathology. J Pathol. 1986 Jun;149(2):79–87. doi: 10.1002/path.1711490202. [DOI] [PubMed] [Google Scholar]
  50. Raymond W. A., Leong A. S., Bolt J. W., Milios J., Jose J. S. Growth fractions in human prostatic carcinoma determined by Ki-67 immunostaining. J Pathol. 1988 Oct;156(2):161–167. doi: 10.1002/path.1711560211. [DOI] [PubMed] [Google Scholar]
  51. Raymond W. A., Leong A. S. Nucleolar organizer regions relate to growth fractions in human breast carcinoma. Hum Pathol. 1989 Aug;20(8):741–746. doi: 10.1016/0046-8177(89)90066-x. [DOI] [PubMed] [Google Scholar]
  52. Raymond W. A., Leong A. S. Oestrogen receptor staining of paraffin-embedded breast carcinomas following short fixation in formalin: a comparison with cytosolic and frozen section receptor analyses. J Pathol. 1990 Apr;160(4):295–303. doi: 10.1002/path.1711600405. [DOI] [PubMed] [Google Scholar]
  53. Raymond W. A., Leong A. S. The relationship between growth fractions and oestrogen receptors in human breast carcinoma, as determined by immunohistochemical staining. J Pathol. 1989 Jul;158(3):203–211. doi: 10.1002/path.1711580306. [DOI] [PubMed] [Google Scholar]
  54. Roggendorf W., Schuster T., Peiffer J. Proliferative potential of meningiomas determined with the monoclonal antibody Ki-67. Acta Neuropathol. 1987;73(4):361–364. doi: 10.1007/BF00688260. [DOI] [PubMed] [Google Scholar]
  55. Sahin A. A., Ro J. Y., el-Naggar A. K., Wilson P. L., Teague K., Blick M., Ayala A. G. Tumor proliferative fraction in solid malignant neoplasms. A comparative study of Ki-67 immunostaining and flow cytometric determinations. Am J Clin Pathol. 1991 Oct;96(4):512–519. doi: 10.1093/ajcp/96.4.512. [DOI] [PubMed] [Google Scholar]
  56. Sahin A. A., Ro J., Ro J. Y., Blick M. B., el-Naggar A. K., Ordonez N. G., Fritsche H. A., Smith T. L., Hortobagyi G. N., Ayala A. G. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer. 1991 Aug 1;68(3):549–557. doi: 10.1002/1097-0142(19910801)68:3<549::aid-cncr2820680318>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  57. Sasaki K., Matsumura K., Tsuji T., Shinozaki F., Takahashi M. Relationship between labeling indices of Ki-67 and BrdUrd in human malignant tumors. Cancer. 1988 Sep 1;62(5):989–993. doi: 10.1002/1097-0142(19880901)62:5<989::aid-cncr2820620525>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  58. Schonk D. M., Kuijpers H. J., van Drunen E., van Dalen C. H., Geurts van Kessel A. H., Verheijen R., Ramaekers F. C. Assignment of the gene(s) involved in the expression of the proliferation-related Ki-67 antigen to human chromosome 10. Hum Genet. 1989 Oct;83(3):297–299. doi: 10.1007/BF00285178. [DOI] [PubMed] [Google Scholar]
  59. Schwarting R., Gerdes J., Niehus J., Jaeschke L., Stein H. Determination of the growth fraction in cell suspensions by flow cytometry using the monoclonal antibody Ki-67. J Immunol Methods. 1986 Jun 10;90(1):65–70. doi: 10.1016/0022-1759(86)90384-4. [DOI] [PubMed] [Google Scholar]
  60. Schwarting R. Little missed markers and Ki-67. Lab Invest. 1993 Jun;68(6):597–599. [PubMed] [Google Scholar]
  61. Shepherd N. A., Richman P. I., England J. Ki-67 derived proliferative activity in colorectal adenocarcinoma with prognostic correlations. J Pathol. 1988 Jul;155(3):213–219. doi: 10.1002/path.1711550306. [DOI] [PubMed] [Google Scholar]
  62. Silvestrini R., Costa A., Veneroni S., Del Bino G., Persici P. Comparative analysis of different approaches to investigate cell kinetics. Cell Tissue Kinet. 1988 Mar;21(2):123–131. doi: 10.1111/j.1365-2184.1988.tb00778.x. [DOI] [PubMed] [Google Scholar]
  63. Swanson S. A., Brooks J. J. Proliferation markers Ki-67 and p105 in soft-tissue lesions. Correlation with DNA flow cytometric characteristics. Am J Pathol. 1990 Dec;137(6):1491–1500. [PMC free article] [PubMed] [Google Scholar]
  64. Tubiana M., Courdi A. Cell proliferation kinetics in human solid tumors: relation to probability of metastatic dissemination and long-term survival. Radiother Oncol. 1989 May;15(1):1–18. doi: 10.1016/0167-8140(89)90113-8. [DOI] [PubMed] [Google Scholar]
  65. Ueda T., Aozasa K., Tsujimoto M., Ohsawa M., Uchida A., Aoki Y., Ono K., Matsumoto K. Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer. 1989 Apr 15;63(8):1607–1611. doi: 10.1002/1097-0142(19890415)63:8<1607::aid-cncr2820630827>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  66. Vollmer E., Roessner A., Gerdes J., Mellin W., Stein H., Chong-Schachel S., Grundmann E. Improved grading of bone tumors with the monoclonal antibody Ki-67. J Cancer Res Clin Oncol. 1986;112(3):281–282. doi: 10.1007/BF00395924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Wintzer H. O., Zipfel I., Schulte-Mönting J., Hellerich U., von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer. 1991 Jan 15;67(2):421–428. doi: 10.1002/1097-0142(19910115)67:2<421::aid-cncr2820670217>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  68. Woods A. L., Hall P. A., Shepherd N. A., Hanby A. M., Waseem N. H., Lane D. P., Levison D. A. The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S+G2+M phase fraction (flow cytometric analysis) and prognosis. Histopathology. 1991 Jul;19(1):21–27. doi: 10.1111/j.1365-2559.1991.tb00890.x. [DOI] [PubMed] [Google Scholar]
  69. Wrba F., Reiner A., Markis-Ritzinger E., Holzner J. H., Reiner G., Spona J. Prognostic significance of immunohistochemical parameters in breast carcinomas. Pathol Res Pract. 1988 Jun;183(3):277–283. doi: 10.1016/S0344-0338(88)80122-5. [DOI] [PubMed] [Google Scholar]
  70. Zuber P., Hamou M. F., de Tribolet N. Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67. Neurosurgery. 1988 Feb;22(2):364–368. doi: 10.1227/00006123-198802000-00015. [DOI] [PubMed] [Google Scholar]
  71. van Dierendonck J. H., Wijsman J. H., Keijzer R., van de Velde C. J., Cornelisse C. J. Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Comparison with BrdUrd labeling and Ki-67 staining. Am J Pathol. 1991 May;138(5):1165–1172. [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Molecular Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES